A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF 006 in Patients With Non-Small Cell Lung, Pancreatic, or Colorectal Cancer
Latest Information Update: 13 Sep 2019
At a glance
- Drugs NBF 006 (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Nitto Biopharma
- 01 Mar 2019 Planned initiation date changed from 1 Feb 2019 to 1 Mar 2019.
- 05 Feb 2019 Status changed from not yet recruiting to recruiting.
- 30 Jan 2019 Status changed from planning to not yet recruiting.